LSBio’s IHC-plus antibodies have been tested and identified as being optimal for use in immunohistochemistry (IHC) against formalin-fixed paraffin-embedded (FFPE) human tissues under LSBio’s standardised IHC-plus immunohistochemistry protocol. Each antibody is tested at multiple concentrations on more than 20 normal human tissue types and, when appropriate, multiple normal brain regions and/or cancer types.
The company’s IHC protocol has been developed over the past 15 years for immunolabelling FFPE tissues, the most common fixation method used by pathology labs worldwide. A LifeSpan pathologist, with extensive experience evaluating IHC, analyses the localisation profile of each antibody, identifying positive and negative cell types, signal strength, subcellular and extracellular staining, and staining artefacts. This information is then compared with all published expression and localisation data available for the protein. This enables LSBio to evaluate how each antibody behaves in IHC, including its specificity to the target protein, its sensitivity of detection and any non-specific staining characteristics that it may display.
In order to be selected as an IHC-plus brand antibody, antibodies must have a close correlation to the published literature, be high affinity, display minimal staining artefacts and have a high signal-to-noise ratio, such that its specific staining is considerably higher than its level of nonspecific background staining.
Phone: 02 9698 2022
Amsbio BioPORTER Protein Delivery Reagent
The BioPORTER Protein Delivery Reagent from Amsbio is a specialised, lipid-based reagent designed...
Amsbio StemFit Basic04CT stem cell medium
StemFit Basic04CT from Amsbio is an animal-origin-free, defined, ready-to-use medium designed to...
Takara Bio Europe Cellartis MSC EV Wonder GMP-grade medium
Takara Bio Europe has introduced a Good Manufacturing Practice (GMP)-grade version of Cellartis...
